New CAR-T therapy aims to prevent relapse in childhood leukemia
NCT ID NCT07575919
First seen May 11, 2026 · Last updated Jun 19, 2026 · Updated 12 times
Summary
This study tests a new immune cell therapy (CAR-T cells that target two proteins, CD22 and CD19) as a consolidation treatment for people with standard-risk B-cell acute lymphoblastic leukemia who are already in remission. The goal is to see if it is safe and can help prevent the cancer from coming back. Twenty participants will receive the therapy and be followed for two years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese PLA General Hospital
RECRUITINGBeijing, Beijing Municipality, 100853, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CD22/CD19 dual-target CAR-T cells (a type of immune cell therapy)
What this could lead to
If successful, this could offer a more effective consolidation therapy for B-ALL patients in remission, potentially lowering relapse rates and improving long-term survival.
What could go wrong
This is an early-phase (Phase 1/2) study with only 20 participants, so results may not apply broadly. Risks include serious side effects like cytokine release syndrome and neurotoxicity.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.